Zobrazeno 1 - 10
of 705
pro vyhledávání: '"ar-v7"'
Autor:
Tryambak Pratap Srivastava, Swati Ajmeriya, Isha Goel, Joyeeta Talukdar, Anurag Srivastava, Rajinder Parshad, S.V.S. Deo, Sandeep R. Mathur, Ajay Gogia, Avdhesh Rai, Ruby Dhar, Subhradip Karmakar
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background The Androgen Receptor (AR) has emerged as an endocrine therapy target in Breast Cancer, exhibiting up to 80% expression in clinical cases. AR-V7, a constitutively activated splice variant of AR with a truncated ligand-binding doma
Externí odkaz:
https://doaj.org/article/7de744008506450da293a1d1e9c0d7dd
Autor:
Maham Khan
Publikováno v:
Annals of Urologic Oncology, Vol 7, Pp 1-8 (2024)
Prostate cancer (PCa) is a malignancy originating from the epithelial cells of the prostate gland, strongly influenced by androgens, and is one of the most common cancers in men. Androgen deprivation therapy (ADT) is the primary treatment for prostat
Externí odkaz:
https://doaj.org/article/d9fb56146383423487a14e0942633b77
Autor:
Jiajia Wang, Hui Liu, Zeyuan Yu, Qianqian Zhou, Feifei Sun, Jingying Han, Lin Gao, Baokai Dou, Hanwen Zhang, Jiawei Fu, Wenqiao Jia, Weiwen Chen, Jing Hu, Bo Han
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background Endocrine resistance driven by sustained activation of androgen receptor (AR) signaling pathway in advanced prostate cancer (PCa) is fatal. Characterization of mechanisms underlying aberrant AR pathway activation to search for pot
Externí odkaz:
https://doaj.org/article/53f2bb0e165443118786ddd413f4b43e
Autor:
Haiyan E. Liu, Meghah Vuppalapaty, Christian R. Hoerner, Colin P. Bergstrom, Michael Chiu, Clementine Lemaire, James Che, Amanpreet Kaur, Adam Dimmick, Sean Liu, Thomas J. Metzner, Menna Araya, Steve Crouse, Markus Sprenger-Haussels, Martin Schlumpberger, John T. Leppert, Siegfried Hauch, Elodie Sollier, Alice C. Fan
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background Therapies for metastatic castration-resistant prostate cancer (mCRPC) include targeting the androgen receptor (AR) with androgen receptor inhibitors (ARIs) and prostate-specific membrane antigen (PSMA). Having the ability to detec
Externí odkaz:
https://doaj.org/article/f147876cb7db462d84fa5bc412a8c4d4
Publikováno v:
Endocrine Oncology, Vol 4, Iss 1, Pp 1-9 (2024)
Androgen receptor (AR) and its constitutively active splice variant, AR Variant 7 (AR-V7), regulate genes essential for the development and progression of prostate cancer. Degradation of AR and AR-V7 by the ubiquitination proteasomal pathway is impor
Externí odkaz:
https://doaj.org/article/934fbf2eb6f847de87e66036da409044
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-12 (2023)
Androgen receptor (AR) plays a vital role in the development and progression of prostate cancer from the primary stage to the usually lethal stage known as castration-resistant prostate cancer (CRPC). Constitutively active AR splice variants (AR-Vs)
Externí odkaz:
https://doaj.org/article/c44a03d2becd435d9797c1541b23dc1b
Publikováno v:
Cells, Vol 13, Iss 1, p 104 (2024)
Therapeutic options for advanced prostate cancer have vastly expanded over the last decade and will continue to expand in the future. Drugs targeting the androgen receptor (AR) signaling pathway, i.e., androgen receptor targeting agents (ARTAs), rema
Externí odkaz:
https://doaj.org/article/51bbd29efee7411c9bf3ef459604643b
Autor:
Rintu Thomas, John Michael Jerome, Truong D. Dang, Eric P. Souto, Joshua N. Mallam, David R. Rowley
Publikováno v:
Cell Communication and Signaling, Vol 20, Iss 1, Pp 1-19 (2022)
Abstract Background Bone metastatic prostate cancer does not completely respond to androgen-targeted therapy and generally evolves into lethal castration resistant prostate cancer (CRPC). Expression of AR-V7- a constitutively active, ligand independe
Externí odkaz:
https://doaj.org/article/f1b470da9df746d18e033a47911f33e8
Autor:
Éva Erdmann, Pauline Ould Madi Berthélémy, Félicie Cottard, Charlotte Zoe Angel, Edwige Schreyer, Tao Ye, Bastien Morlet, Luc Negroni, Bruno Kieffer, Jocelyn Céraline
Publikováno v:
Molecular Oncology, Vol 16, Iss 13, Pp 2518-2536 (2022)
Androgen receptor (AR) signaling remains the key therapeutic target in the management of hormone‐naïve‐advanced prostate cancer (PCa) and castration‐resistant PCa (CRPC). Recently, landmark molecular features have been reported for CRPC, inclu
Externí odkaz:
https://doaj.org/article/47c6001aa48b46609adfd526b321c261
Autor:
Lei Xia, Qing Han, Xuehui Duan, Yinjie Zhu, Jiahua Pan, Baijun Dong, Weiliang Xia, Wei Xue, Jianjun Sha
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 28, Iss , Pp 219-230 (2022)
Androgen receptor splice variant 7 (AR-v7), a constitutively active transcription factor, plays a crucial role in the progression of castration-resistant prostate cancer (CRPC). Here, we found that the cleavage and polyadenylation specificity factor
Externí odkaz:
https://doaj.org/article/2953ca1c159b4ad49b7ab5096a5d4487